Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 4Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 159Neoplasms 116Carcinoma, Non-Small-Cell Lung 91Colorectal Neoplasms 86Prostatic Neoplasms 85Lung Neoplasms 78Leukemia, Myeloid, Acute 54Carcinoma, Hepatocellular 52Pancreatic Neoplasms 46Neoplasm Metastasis 44Multiple Myeloma 38Recurrence 35Triple Negative Breast Neoplasms 31Squamous Cell Carcinoma of Head and Neck 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Ovarian Neoplasms 29Melanoma 28Uterine Cervical Neoplasms 27Stomach Neoplasms 27Glioblastoma 27Brain Neoplasms 27Rectal Neoplasms 25Head and Neck Neoplasms 25Small Cell Lung Carcinoma 23Carcinoma, Renal Cell 23Endometrial Neoplasms 20Lymphoma, B-Cell 19Glioma 19Sarcoma 18Lymphoma, Follicular 18

Interventions

ribociclib 1exemestane 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Letrozole 1Drug Therapy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Anatomic Stage II Breast Cancer AJCC v8 × 90 days × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡